Evidence map›Paper›PMID 34737296›Full record

Trial reportSignal transduction and targeted therapy2021

Restoration of HBV-specific CD8

Dongyao Wang, Binqing Fu, Xiaokun Shen, Chuang Guo, Yanyan Liu, Junfei Zhang, Rui Sun, Ying Ye, Jiabin Li, Zhigang Tian and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Hepatitis B: Model Systems and Therapeutic Approaches.Journal of immunology research · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dongyao Wang *Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Binqing Fu *Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Xiaokun ShenInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Chuang GuoInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Yanyan LiuDepartment of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230027, China.
Junfei ZhangDepartment of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230027, China.
Rui SunInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Ying YeDepartment of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230027, China.
Jiabin LiDepartment of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230027, China. lijiabin@ahmu.edu.cn.
Zhigang TianInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China. tzg@ustc.edu.cn.
Haiming WeiInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China. ustcwhm@ustc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies aimed at CHB. This study comprised two clinical trials, including 130 CHB patients, who were treatment-naïve; in the first, 92 patients were systematically analyzed ex vivo for interleukin-2 receptor (IL-2R) expression and inhibitory molecules expression after receiving Peg-IFN-α-2b therapy. In our second clinical trial, 38 non-responder patients, in whom IFN-α therapy had failed, were treated with or without low-dose IL-2 for 24 weeks. We then examined the hepatitis B virus (HBV)-specific CD8

Indexed as

Hepatitis B, ChronicInterferon-alphaInterleukin-2Interleukin-2 Receptor alpha SubunitRecombinant ProteinsAdolescentAdultAgedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDrug Resistance, ViralFemaleGene Expression RegulationHepatitis B e AntigensHepatitis B virusHumansgamma interferon activation factorHepatitis B e AntigensIL2RA protein, humanInterferon-alphaInterferon-Stimulated Gene Factor 3Interleukin-2Interleukin-2 Receptor alpha SubunitProgrammed Cell Death 1 ReceptorRecombinant Proteins

Identifiers

PMID34737296
PMCPMC8569154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.